88,510 Shares in Maze Therapeutics, Inc. $MAZE Bought by Exome Asset Management LLC

Exome Asset Management LLC acquired a new position in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 88,510 shares of the company’s stock, valued at approximately $2,642,000.

Other hedge funds have also bought and sold shares of the company. Washington University boosted its stake in shares of Maze Therapeutics by 33.3% during the 4th quarter. Washington University now owns 280,802 shares of the company’s stock worth $11,634,000 after purchasing an additional 70,121 shares during the period. Mass General Brigham Inc purchased a new stake in Maze Therapeutics in the 4th quarter worth about $9,943,000. Boothbay Fund Management LLC raised its position in Maze Therapeutics by 16.3% in the 4th quarter. Boothbay Fund Management LLC now owns 409,372 shares of the company’s stock worth $16,960,000 after purchasing an additional 57,497 shares during the period. Eventide Asset Management LLC bought a new stake in Maze Therapeutics in the fourth quarter worth about $13,425,000. Finally, Spruce Street Capital LP bought a new stake in Maze Therapeutics in the first quarter worth about $5,970,000.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Wall Street Zen raised Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. JPMorgan Chase & Co. boosted their price objective on Maze Therapeutics from $52.00 to $58.00 and gave the company an “overweight” rating in a report on Tuesday, March 31st. Finally, Truist Financial cut their price objective on Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating on the stock in a research report on Tuesday, April 14th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $66.00.

Maze Therapeutics Trading Up 3.6%

Shares of MAZE opened at $28.69 on Tuesday. The firm has a market capitalization of $1.59 billion, a price-to-earnings ratio of -11.34 and a beta of 2.14. The company has a debt-to-equity ratio of 0.11, a current ratio of 17.88 and a quick ratio of 17.88. Maze Therapeutics, Inc. has a 1-year low of $12.81 and a 1-year high of $53.65. The company has a 50-day moving average of $27.19 and a 200 day moving average of $34.36.

Maze Therapeutics (NASDAQ:MAZE) last issued its earnings results on Tuesday, May 12th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). The business had revenue of $20.00 million for the quarter. On average, research analysts expect that Maze Therapeutics, Inc. will post -2.73 EPS for the current year.

Insider Activity at Maze Therapeutics

In related news, CMO Harold Bernstein sold 14,609 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $29.90, for a total value of $436,809.10. Following the transaction, the chief marketing officer owned 14,609 shares of the company’s stock, valued at $436,809.10. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of the firm’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $28.02, for a total value of $210,150.00. Following the transaction, the insider owned 26,250 shares in the company, valued at $735,525. The trade was a 22.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 141,470 shares of company stock worth $3,887,939. Company insiders own 5.30% of the company’s stock.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.